54.32
price up icon4.74%   2.46
after-market 시간 외 거래: 54.32
loading
전일 마감가:
$51.86
열려 있는:
$52.3
하루 거래량:
217.32K
Relative Volume:
0.73
시가총액:
$3.43B
수익:
-
순이익/손실:
$-54.80M
주가수익비율:
-46.46
EPS:
-1.1692
순현금흐름:
$-64.65M
1주 성능:
+11.24%
1개월 성능:
+13.17%
6개월 성능:
+36.11%
1년 성능:
+19.89%
1일 변동 폭
Value
$51.42
$54.93
1주일 범위
Value
$47.33
$54.93
52주 변동 폭
Value
$37.55
$64.98

문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile

Name
명칭
Moonlake Immunotherapeutics
Name
전화
41 41 510 8022
Name
주소
DORFSTRASSE 29, ZUG
Name
직원
50
Name
트위터
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
MLTX's Discussions on Twitter

MLTX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
MLTX 54.32 3.43B 0 -54.80M -64.65M -1.1692
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-02-15 개시 Wolfe Research Outperform
2023-12-08 개시 Citigroup Buy
2023-11-02 개시 Stifel Buy
2023-09-14 다운그레이드 Bryan Garnier Buy → Neutral
2023-08-31 개시 Needham Buy
2023-06-15 개시 Barclays Equal Weight
2023-05-01 개시 Guggenheim Buy
2023-03-22 개시 Wedbush Outperform
2023-03-09 개시 BTIG Research Buy
2023-02-14 개시 Cantor Fitzgerald Overweight
2023-02-02 개시 Bryan Garnier Buy
2022-11-11 개시 Jefferies Buy
2022-08-25 개시 SVB Leerink Outperform
2022-07-21 개시 H.C. Wainwright Buy
2022-07-07 개시 Cowen Outperform
모두보기

문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스

pulisher
02:39 AM

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

02:39 AM
pulisher
Nov 21, 2024

MoonLake Immunotherapeutics: A Somewhat Complicated Story (NASDAQ:MLTX) - Seeking Alpha

Nov 21, 2024
pulisher
Nov 21, 2024

Victory Capital Management Inc. Has $10.98 Million Stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 21, 2024
pulisher
Nov 20, 2024

MoonLake Immunotherapeutics Reports Q3 2024 Financial Results - MSN

Nov 20, 2024
pulisher
Nov 14, 2024

MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

MoonLake Immunotherapeutics' SWOT analysis: biopharma stock faces HS market potential, execution risks - Investing.com Canada

Nov 14, 2024
pulisher
Nov 13, 2024

(MLTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 13, 2024
pulisher
Nov 13, 2024

MoonLake Immunotherapeutics announces first patients screened in IZAR program - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

MoonLake Launches Major Phase 3 Trials for Psoriatic Arthritis Drug After Strong Phase 2 Results | MLTX Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 12, 2024

FMR LLC's Strategic Acquisition of MoonLake Immunotherapeutics S - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

MoonLake Immunotherapeutics (MLTX) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 09, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Q3 Earnings Forecast for MLTX Issued By Wedbush - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

What is Wedbush's Forecast for MLTX Q3 Earnings? - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

MoonLake Immunotherapeutics reports Q3 EPS (56c), consensus (43c) - TipRanks

Nov 07, 2024
pulisher
Nov 07, 2024

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

MoonLake Reports $493.9M Cash Position, Advances Multiple Phase 3 Trials | MLTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to "Strong-Buy" at Wedbush - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Wedbush Reiterates "Outperform" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 05, 2024
pulisher
Nov 05, 2024

AlphaCentric Advisors LLC Invests $706,000 in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Nov 05, 2024
pulisher
Nov 04, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Long Term Trading Analysis for (MLTX) - Stock Traders Daily

Nov 03, 2024
pulisher
Nov 02, 2024

75,469 Shares in MoonLake Immunotherapeutics (NASDAQ:MLTX) Acquired by Rice Hall James & Associates LLC - MarketBeat

Nov 02, 2024
pulisher
Oct 30, 2024

MLTX Makes Notable Cross Below Critical Moving Average - Nasdaq

Oct 30, 2024
pulisher
Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $80.45 Average PT from Brokerages - MarketBeat

Oct 29, 2024
pulisher
Oct 29, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Oct 29, 2024
pulisher
Oct 26, 2024

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts - MSN

Oct 26, 2024
pulisher
Oct 25, 2024

I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin - TheStreet

Oct 25, 2024
pulisher
Oct 24, 2024

This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St

Oct 24, 2024
pulisher
Oct 23, 2024

(MLTX) Proactive Strategies - Stock Traders Daily

Oct 23, 2024
pulisher
Oct 17, 2024

HC Wainwright Reiterates “Buy” Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares By Investing.com - Investing.com Nigeria

Oct 16, 2024
pulisher
Oct 16, 2024

H.C. Wainwright maintains buy rating on Moonlake Immunotherapeutics shares - Investing.com India

Oct 16, 2024
pulisher
Oct 15, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 15, 2024
pulisher
Oct 13, 2024

MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold (NASDAQ:MLTX) - Seeking Alpha

Oct 13, 2024
pulisher
Oct 12, 2024

When (MLTX) Moves Investors should Listen - Stock Traders Daily

Oct 12, 2024
pulisher
Oct 10, 2024

MoonLake Immunotherapeutics [MLTX] stock for 100,003,200 USD was sold by BVF PARTNERS L P/IL - Knox Daily

Oct 10, 2024
pulisher
Oct 10, 2024

MLTX’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Investor’s Toolkit: Key Ratios for Assessing MoonLake Immunotherapeutics (MLTX)’s Performance - The Dwinnex

Oct 10, 2024
pulisher
Oct 09, 2024

What is MLTX’s price-to-sales ratio telling us about the company’s value? - US Post News

Oct 09, 2024
pulisher
Oct 09, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down on Insider Selling - Defense World

Oct 09, 2024
pulisher
Oct 09, 2024

Millennium Management LLC Has $9.54 Million Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat

Oct 09, 2024
pulisher
Oct 09, 2024

Biotechnology value fund L P executives sell over $100 million in MoonLake Immunotherapeutics shares - Investing.com India

Oct 09, 2024
pulisher
Oct 08, 2024

MoonLake Immunotherapeutics director sells shares worth over $9m - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Insider Selling: MoonLake Immunotherapeutics (NASDAQ:MLTX) Director Sells 171,000 Shares of Stock - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Simon Sturge Sells 171,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

MoonLake Immunotherapeutics director sells shares worth over $9m By Investing.com - Investing.com UK

Oct 08, 2024
pulisher
Oct 08, 2024

Director Simon Sturge Sells 171,000 Shares of MoonLake Immunothe - GuruFocus.com

Oct 08, 2024
pulisher
Oct 07, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 8.3%Here's What Happened - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

MoonLake Immunotherapeutics (NASDAQ:MLTX) Position Increased by The Manufacturers Life Insurance Company - MarketBeat

Oct 07, 2024

문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Sturge Simon
Director
Oct 04 '24
Sale
53.72
171,000
9,186,120
171,980
Santos da Silva Jorge
Chief Executive Officer
Feb 27 '24
Sale
55.00
62,810
3,454,550
3,043,619
Santos da Silva Jorge
Chief Executive Officer
Feb 28 '24
Sale
55.00
56,065
3,083,575
2,987,554
Santos da Silva Jorge
Chief Executive Officer
Feb 29 '24
Sale
55.89
4,740
264,919
2,982,814
Reich Kristian
Chief Scientific Officer
Feb 28 '24
Sale
55.00
31,910
1,755,050
2,925,573
Reich Kristian
Chief Scientific Officer
Feb 27 '24
Sale
55.00
29,491
1,622,005
2,957,483
Reich Kristian
Chief Scientific Officer
Feb 27 '24
Sale
55.00
29,431
1,618,705
70,071
Reich Kristian
Chief Scientific Officer
Feb 28 '24
Sale
55.00
28,090
1,544,950
41,981
Santos da Silva Jorge
Chief Executive Officer
Feb 21 '24
Sale
55.27
1,125
62,179
3,106,429
Reich Kristian
Chief Scientific Officer
Feb 20 '24
Sale
57.45
10,000
574,500
2,987,483
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):